Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

People with schizophrenia can experience psychosis, a condition in which they perceive the world very differently to those around them. They may see or hear things that others cannot or hold beliefs that others find bizarre. These experiences can be distressing for those experiencing them, as well as for their families and friends. Current treatments are inadequate: they do not work for all and can lead to unpleasant side effects. But attempts to improve this are hampered by our limited understanding of schizophrenia’s biological basis.

There is no single factor that causes schizophrenia, but we know that genes are important. But neither is there a “schizophrenia gene”. Instead, many hundreds of genes act in concert to subtly increase or decrease how likely we are to become ill, given the environment in which we find ourselves.

In the last ten years, geneticists have begun to uncover the specifics of these complex relationships by identifying precisely which genes are linked with schizophrenia and other mental health conditions. For neurobiologists like me, the discovery of these genes is exciting. This information provides new clues as to which molecules and cell signalling pathways might be altered in these conditions.

Read the full article on The Conversation website, written by Dr Elizabeth Tunbridge, Associate Professor, Department of Psychiatry.

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.